A P. falciparum MSP1 p42/QS-21 malaria vaccine

Award Information
Agency:
Department of Health and Human Services
Branch:
N/A
Amount:
$302,541.00
Award Year:
2001
Program:
STTR
Phase:
Phase I
Contract:
PHS2001-2
Agency Tracking Number:
1R41AI049641-01
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ANTIGENICS, INC.
34 COMMERCE WAY, WOBURN, MA 01801-1065, WOBURN, MA, 01801
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
N/A
Principal Investigator
 SANDRA CHANG
 (808) 732-1477
 sandrac@hawaii.edu
Business Contact
 PACKARD, MELISSA
Phone: (781) 721-3518
Email: MPACKARD@AQUILABIO.COM
Research Institution
 UNIVERSITY OF HAWAII
 UNIVERSITY OF HAWAII
HONOLULU, HI, 96750
 Nonprofit college or university
Abstract
DESCRIPTION: (Adapted from Applicant's Abstract) Malaria is a disease which affects more than 300 million people each year and is fatal for 1.5 million. The overall objective of this STTR Phase I project is to produce a cGMP malaria vaccine consisting of the 42 kDa C-terminal polypeptide of P. falciparum merozoite surface protein-1 (MSP1.42) to be formulated with QS21 adjuvant for preclinical studies and a future clinical Phase I trial. Evidence is presented that MSP1.42/QS-21 protects against P. falciparum malaria in the Aotus monkey model. Data is also presented supporting the feasibility of large-scale MSP1.42 production in the baculovirus system and its purification by standard chromatography. The goals of the project are (1) production of master cell banks of insect cell lines for virus stock and polypeptide production, respectively; (2) preparation of a virus stock of recombinant MSP1.42 baculovirus; (3) production of bulk MSP1.42 antigen in a bioreactor; (4) purification of MSP1.42; (5) establishment of analytical methods to define product specifications; and (6) evaluation of the immunogenicity of the cGMP MSP1.42/QS21 formulation in mice and Aotus and of its efficacy in Aotus. These studies will provide cGMP material and preclinical information for a clinical trial of MSP1.42/QS21 during STTR Phase II. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government